Real-world utilization patterns of PI and IMiD combination therapy as treatment for relapse multiple myeloma.

被引：1
|
作者：
Maiese, Eric M.
Slaton, Terra
Macomson, Brian
Kozma, Chris M.
机构：
[1] Janssen Sci Affairs LLC, Horsham, PA USA
[2] CK Consulting, W Columbia, SC USA
[3] CK Consulting, St Helena Island, SC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.8052
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8052
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Current real-world treatment patterns and outcomes in patients with relapsed/refractory multiple myeloma.
    Willson, Jenny
    Bruno, Amanda
    Opalinska, Joanna
    Nelson, Jeanenne Joy
    Lunacsek, Orsolya
    Stafkey-Mailey, Dana
    Willey, Joanne P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD
    Usmani, Saad
    Ahmadi, Tahamtan
    Ng, Yvette
    Lam, Annette
    Desai, Avinash
    Potluri, Ravi
    Mehra, Maneesha
    [J]. ONCOLOGIST, 2016, 21 (11): : 1355 - 1361
  • [3] ANALYSIS OF OVERALL SURVIVAL IN MULTIPLE MYELOMA PATIENTS WITH 33 LINES OF THERAPY INCLUDING A PI AND AN IMID, OR DOUBLE REFRACTORY TO A PI AND AN IMID USING REAL WORLD DATA
    Usmani, S.
    Desai, A.
    Ahmadi, T.
    Ng, Y.
    Sung, G.
    Mehra, M.
    [J]. HAEMATOLOGICA, 2015, 100 : 504 - 505
  • [4] Real-World Treatment Patterns and Outcomes of Patients with Functional High-Risk (Early Relapse) Multiple Myeloma
    Belli, Andrew J.
    Hansen, Eric
    Kansagra, Ankit
    Dilwali, Keshava
    Wang, Ching-Kun
    [J]. BLOOD, 2020, 136
  • [5] Minimal Residual Disease Perception and Utilization in Real-World Multiple Myeloma Treatment
    Jennings, Luke
    Gajra, Ajeet
    Balijevic, Muhamed
    Smith, Yolaine
    Feinberg, Bruce
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S425 - S426
  • [6] EARLY DEATH IN MULTIPLE MYELOMA. ANALYSIS OF PATIENTS IN REAL-WORLD PRACTICE
    Lakhwani Lakhwani, S.
    Hernandez Garcia, M. T.
    Lorenzo Barreto, P.
    Cabrera Brito, D.
    Fernandez Gonzalez, M.
    Diaz Gomez, M.
    Raya Sanchez, J. M.
    [J]. HAEMATOLOGICA, 2019, 104 : 14 - 15
  • [7] Biological relapse in multiple myeloma: Outcome and treatment strategies in a Spanish real-world setting
    Alegre, Adrian
    Gironella, Mercedes
    Escalante, Fernando
    Bergua, Juan M.
    Martinez-Chamorro, Carmen
    Lopez, Aurelio
    Gonzalez, Esther
    Barez, Abelardo
    Somolinos, Nieves
    Persona, Ernesto P.
    Cabrera, Alexia S.
    Soler, Alfons
    Rodriguez, Belen I.
    Lopez, Joaquin M.
    Gonzalez, Yolanda
    Gimenez, Veronica C.
    Sampol, Antonia
    Munoz, Carolina
    Vilanova, David
    Duran, Marta
    de Larrea, Carlos Fernandez
    [J]. HEMASPHERE, 2024, 8 (07):
  • [8] Real-world treatment patterns and outcomes in lenalidomide refractory multiple myeloma patients in Europe: a real-world survey
    Martinez-Lopez, Joaquin
    Mendes, Joao
    Luke, Emily
    Kluth, Caspian
    Salmon, Phoebe
    Bailey, Abigail
    Ribbands, Amanda
    Gay, Francesca
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S198 - S199
  • [9] Analyses of Real World Data on Overall Survival in Multiple Myeloma Patients with at Least 3 Prior Lines of Therapy Including a PI and an IMiD, or Double Refractory to a PI and an IMiD
    Usmani, Saad
    Ahmadi, Tahamtan
    Ng, Yvette
    Lam, Annette
    Potluri, Ravi
    Mehra, Maneesha
    [J]. BLOOD, 2015, 126 (23)
  • [10] REAL-WORLD TREATMENT PATTERNS AND PATIENTS CHARACTERISTICS IN MULTIPLE MYELOMA ACROSS EUROPE
    Fernandez, A.
    Zomas, A.
    Papakostas, E.
    Do, T.
    Russo, M.
    D'Ambrosio, R.
    Schneidewind, G.
    [J]. HAEMATOLOGICA, 2017, 102 : 517 - 518
12345